NASDAQ:ICLR - Icon Stock Price, Price Target & More

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Icon Plc (NASDAQ:ICLR) issued its quarterly earnings data on Thursday, May, 3rd. The medical research company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.41 by $0.01. The medical research company had revenue of $620.13 million for the quarter, compared to analysts' expectations of $562.61 million. Icon had a net margin of 14.80% and a return on equity of 26.56%. The business's revenue was up 43.6% on a year-over-year basis. During the same quarter last year, the company earned $1.29 EPS. View Icon's Earnings History.

Icon is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Icon.

Icon updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $5.91-6.11 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.99. The company issued revenue guidance of $2.52-2.64 billion, compared to the consensus revenue estimate of $2.25 billion.

9 Wall Street analysts have issued twelve-month target prices for Icon's shares. Their predictions range from $114.00 to $152.00. On average, they anticipate Icon's stock price to reach $132.2222 in the next year. This suggests that the stock has a possible downside of 3.4%. View Analyst Ratings for Icon.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

Media stories about ICLR stock have trended somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Icon earned a daily sentiment score of 0.13 on Accern's scale. They also gave news coverage about the medical research company an impact score of 46.10 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Icon's stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.53%), Mckinley Capital Management LLC Delaware (0.50%), Bank of Montreal Can (0.33%), LVM Capital Management Ltd. MI (0.10%), Welch & Forbes LLC (0.04%) and Fisher Asset Management LLC (0.04%). View Institutional Ownership Trends for Icon.

ICLR stock was sold by a variety of institutional investors in the last quarter, including Mckinley Capital Management LLC Delaware, Peregrine Capital Management LLC, Reliance Trust Co. of Delaware, Fulton Bank N.A. and Welch & Forbes LLC. View Insider Buying and Selling for Icon.

ICLR stock was acquired by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Bank of Montreal Can, Campbell & CO Investment Adviser LLC, LVM Capital Management Ltd. MI, Atria Investments LLC and Fisher Asset Management LLC. View Insider Buying and Selling for Icon.

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ICLR stock can currently be purchased for approximately $136.85.

Icon has a market capitalization of $7.48 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe.

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.